Findings

What do systematic reviews say?

3 questions · 3 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 66.7%High 1 · 33.3%

Topical imiquimod 5% (3 times/week) + meglumine antimoniate (IVMA) (20 mg/kg/d for 20 days) vs placebo + IVMA

Adverse effects (number of participants who had the event) · People with American cutaneous leishmaniasis

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 80 participants
High

Oral miltefosine (50 mg for 28 days) vs 28 days on/off placebo regimen

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (50 mg for 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with placebo (same regimen) (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 3.96 [1.49, 10.48]
1 study · 133 participants
Moderate

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) vs meglumine antimoniate (20 mg/kg 20 days)

Adverse effects (number of participants who had the event) · People with American cutaneous and mucocutaneous leishmaniasis

Oral miltefosine (1.2 to 3.3 mg/kg/d 28 days) probably leads to higher adverse effects (number of participants who had the event) compared with meglumine antimoniate (20 mg/kg 20 days) (moderate certainty).

1 finding from 1 review

Interventions for American cutaneous and mucocutaneous leishmaniasis 2020 · Cochrane Headline outcomes only
RR 2.45 [1.72, 3.49]
3 studies · 464 participants
Moderate